You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
現代製藥(600420.SH):原料藥鹽酸氨溴索、鹽酸倍他司汀通過CDE技術審評
格隆匯 03-22 18:13

格隆匯3月22日丨現代製藥(600420.SH)宣佈,近日,公司控股子公司上海現代哈森(商丘)藥業有限公司(簡稱“現代哈森”)的原料藥鹽酸氨溴索、鹽酸倍他司汀通過國家藥品監督管理局藥品審評中心(簡稱“CDE”)技術審評,在CDE原料藥、藥用輔料和藥包材登記信息公示平台上顯示登記號轉為“A”狀態。

鹽酸氨溴索為祛痰鎮咳藥物,對於急、慢性呼吸道疾病,如急慢性支氣管炎、支氣管哮喘、支氣管擴張、肺結核等引起的痰液粘稠、咳痰困難等都具有較好的療效。現代哈森針對該原料藥的研發投入約為人民幣265.70萬元。目前,CDE登記平台顯示鹽酸氨溴索“已激活”廠家共18家(含現代哈森)。

鹽酸倍他司汀屬於血管擴張藥,對心、腦、血管都有擴張作用,可用於腦動脈硬化、缺血性腦血管病,也用於高血壓病所致的直立性眩暈、耳鳴等症,以及由於腦供血不足引起的眩暈、頭暈等。現代哈森針對該原料藥的研發投入約為人民幣394.56萬元。目前,CDE登記平台顯示鹽酸倍他司汀“已激活”廠家共6家(含現代哈森)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account